These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47 related articles for article (PubMed ID: 21684085)
1. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer? Veljkovic M; Branch DR; Dopsaj V; Veljkovic V; Veljkovic N; Glisic S; Colombatti A Med Hypotheses; 2011 Sep; 77(3):404-8. PubMed ID: 21684085 [TBL] [Abstract][Full Text] [Related]
2. Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease. Veljkovic V; Metlas R Int Rev Immunol; 2004; 23(5-6):437-45. PubMed ID: 15370275 [TBL] [Abstract][Full Text] [Related]
3. Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1. Veljkovic M; Dopsaj V; Stringer WW; Sakarellos-Daitsiotis M; Zevgiti S; Veljkovic V; Glisic S; Dopsaj M Scand J Med Sci Sports; 2010 Jun; 20(3):469-74. PubMed ID: 19538533 [TBL] [Abstract][Full Text] [Related]
4. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Brenneman DE; Westbrook GL; Fitzgerald SP; Ennist DL; Elkins KL; Ruff MR; Pert CB Nature; 1988 Oct; 335(6191):639-42. PubMed ID: 2845276 [TBL] [Abstract][Full Text] [Related]
5. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. Veljkovic N; Branch DR; Metlas R; Prljic J; Vlahovicek K; Pongor S; Veljkovic V J Pept Res; 2003 Oct; 62(4):158-66. PubMed ID: 12969195 [TBL] [Abstract][Full Text] [Related]
6. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. Veljkovic N; Branch DR; Metlas R; Prljic J; Manfredi R; Stringer WW; Veljkovic V J Clin Virol; 2004 Dec; 31 Suppl 1():S39-44. PubMed ID: 15567092 [TBL] [Abstract][Full Text] [Related]
7. Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy. Veljkovic M; Dopsaj V; Dopsaj M; Branch DR; Veljkovic N; Sakarellos-Daitsiotis MM; Veljkovic V; Glisic S; Colombatti A PLoS One; 2011; 6(11):e28304. PubMed ID: 22140573 [TBL] [Abstract][Full Text] [Related]
8. [AIDS and sleep disorders: effect of gp120 on cerebral glucose metabolism]. Raymon LP; Kimes AS; Tabakoff B; London ED C R Seances Soc Biol Fil; 1989; 183(5):407-18. PubMed ID: 2561668 [TBL] [Abstract][Full Text] [Related]
9. The role of passive immunization in hiv-positive patients : a case report. Veljkovic V; Metlas R; Jevtovic D; Stringer WW Chest; 2001 Aug; 120(2):662-6. PubMed ID: 11502675 [TBL] [Abstract][Full Text] [Related]
10. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS. Veljkovic V; Metlas R; Raspopovic J; Pongor S Biochem Biophys Res Commun; 1992 Dec; 189(2):705-10. PubMed ID: 1472041 [TBL] [Abstract][Full Text] [Related]
12. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Valdehita A; Bajo AM; Fernández-Martínez AB; Arenas MI; Vacas E; Valenzuela P; Ruíz-Villaespesa A; Prieto JC; Carmena MJ Peptides; 2010 Nov; 31(11):2035-45. PubMed ID: 20691743 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature. Oluwole SF; Ali AO; Shafaee Z; DePaz HA J Surg Oncol; 2005 Jan; 89(1):23-7. PubMed ID: 15612013 [TBL] [Abstract][Full Text] [Related]
14. Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies. Ahmad A; Ladha A; Cohen EA; Menezes J Virology; 1993 Feb; 192(2):447-57. PubMed ID: 8421893 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916 [TBL] [Abstract][Full Text] [Related]
16. [Human monoclonal antibodies to HIV-1 infection]. Kawai M; Okada N Nihon Rinsho; 2002 Mar; 60(3):570-7. PubMed ID: 11904975 [TBL] [Abstract][Full Text] [Related]
17. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide. Kelker HC; Schlesinger D; Valentine FT J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976 [TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605 [TBL] [Abstract][Full Text] [Related]
19. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249 [TBL] [Abstract][Full Text] [Related]
20. The antigenic structure of the HIV gp120 envelope glycoprotein. Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]